Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Yuto Nakajima, MD, Keiji Nogami, MD PhD, Hiroaki Minami, MD, Kana Sasai, Midori Shima, MD PhD

Blood (2019) 134 (Supplement_1): 1107.

https://doi.org/10.1182/blood-2019-129313

Published: 2019

Journal Articles

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Shoko Furukawa, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2018-99-114355

Published: 2018

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Coagulation and Fibrinolysis Imbalance Demonstrated By Novel Simultaneous Thrombin and Plasmin Generation Assay during L-Asparaginase Treatment Phase of Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Takashi Ishihara, MD, Keiji Nogami, MD PhD, Satoshi Ochi, MD, Toshiaki Ishida, MD PhD, Yoshiyuki Kosaka, MD PhD, Akihisa Sawada, MD PhD, Masami Inoue, MD, Shinya Osone, MD PhD, Toshihiko Imamura, MD PhD, Hajime Hosoi, MD PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2018-99-110411

Published: 2018

Journal Articles

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio, Jr., Johannes Oldenburg, Victor Jimenez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Tiffany Chang, Marianne Uguen, Michelle Doral, Christophe Schmitt, Gallia G. Levy, Midori Shima, MD PhD, Maria Elisa Mancuso

Blood (2018) 132 (Supplement 1): 632.

https://doi.org/10.1182/blood-2018-99-118153

Published: 2018

Journal Articles

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3782.

https://doi.org/10.1182/blood-2018-99-117877

Published: 2018

Journal Articles

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Kenichi Ogiwara, MD PhD, Hiroki Horiuchi, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2018-99-118379

Published: 2018

Journal Articles

Contribution of Factor VIII A3 Domain Residues 1793-1795 to a Factor IXa-Interactive Site

Masahiro Takeyama, Keiji Nogami, MDPhD, Kana Sasai, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1173.

https://doi.org/10.1182/blood-2018-99-113260

Published: 2018

Journal Articles

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Victor Jimenez-Yuste, Midori Shima, MD PhD, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 1187.

https://doi.org/10.1182/blood-2018-99-118132

Published: 2018

Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD

Blood (2018) 132 (Supplement 1): 1186.

https://doi.org/10.1182/blood-2018-99-115792

Published: 2018

Journal Articles

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

Yuto Nakajima, MD, Koji Yada, MD PhD, Keiji Nogami, MDPhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2018-99-115645

Published: 2018

Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2018-99-118504

Published: 2018

Journal Articles

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yuka Tabuchi, Tetsuhiro Soeda, PhD, Nobuo Arai, Takehisa Kitazawa, Hidenari Takaoka, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1388.

https://doi.org/10.1182/blood.V128.22.1388.1388

Published: 2016

Journal Articles

Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain

Furukawa Shoko, Keiji Nogami, MD PhD, Kenichi Ogiwara, MD PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1391.

https://doi.org/10.1182/blood.V128.22.1391.1391

Published: 2016

Journal Articles

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Arisa Takenaka, Takeshi Kawamura, Midori Shima, MD PhD

Blood (2016) 128 (22): 1392.

https://doi.org/10.1182/blood.V128.22.1392.1392

Published: 2016

Journal Articles

Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study

Johnny Mahlangu, Johannes Oldenburg, Prof, Michael U Callaghan, MD, Midori Shima, MD PhD, Elena Santagostino, MD PhD, Michaela Lehle, PhD, Marianne Uguen, MSc, Ceri Hirst, PhD, Maggie Moore, RN, Michael Recht, MD PhD, Claudia Garcia, MD, Renchi Yang, MD PhD, Rebecca Kruse-Jarres, MD MPH

Blood (2016) 128 (22): 3800.

https://doi.org/10.1182/blood.V128.22.3800.3800

Published: 2016

Journal Articles

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Shoko Furukawa, MD, Midori Shima, MD PhD

Blood (2016) 128 (22): 3760.

https://doi.org/10.1182/blood.V128.22.3760.3760

Published: 2016

Journal Articles

Identification of a Protein S-Interactive Site on the Factor VIII C2 Domain

Furukawa Shoko, Masahiro Takeyama, MD PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2016) 128 (22): 3763.

https://doi.org/10.1182/blood.V128.22.3763.3763

Published: 2016

Journal Articles

Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

Takashi Ishihara, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yasufumi Takeshita, MD, Akitaka Nomura, MD, Satoshi Ochi, MD, Toshiaki Ishida, MD PhD, Yoshiyuki Kosaka, MD PhD, Akihisa Sawada, PhD MD, Masami Inoue, MD, Midori Shima, MD PhD

Blood (2016) 128 (22): 5156.

https://doi.org/10.1182/blood.V128.22.5156.5156

Published: 2016

Journal Articles

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

Hiroaki Yaoi, MD, Yasuaki Shida, MD PhD, Takehisa Kitazawa, Kunihiro Hattori, PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2016) 128 (22): 83.

https://doi.org/10.1182/blood.V128.22.83.83

Published: 2016

NARROW

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Coagulation and Fibrinolysis Imbalance Demonstrated By Novel Simultaneous Thrombin and Plasmin Generation Assay during L-Asparaginase Treatment Phase of Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Contribution of Factor VIII A3 Domain Residues 1793-1795 to a Factor IXa-Interactive Site

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Mechanism of Tissue Factor (TF) Enhancing Factor (F)VIII Activity on FXa Generation in Initial Phase of Coagulation and Interaction Between TF and FVIII C2 Domain

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study

Identification of a Factor X-Interactive Site on the Factor VIII A2 Domain

Identification of a Protein S-Interactive Site on the Factor VIII C2 Domain

Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only